| Feb 11 |
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
|
| Feb 10 |
Actinium Announces Participation in BIO CEO & Investor Digital Conference
|
| Jan 20 |
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
|
| Jan 13 |
Actinium, Astellas in research pact for radiotherapies
|
| Jan 13 |
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
|
| Jan 2 |
Wall Street Breakfast: What Moved Markets
|
| Dec 29 |
Actinium down 22% on independent data monitoring committee recommendation for Iomab-B trial
|
| Dec 29 |
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
|
| Dec 9 |
Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know
|
| Dec 9 |
Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit
|
| Dec 8 |
Benzinga Global Small Cap Conference Day 1 Recap: Sorrento, Arcimoto And Much More
|
| Dec 8 |
Actinium Pharmaceuticals rises 2% after seeing 67% ORR in first cohort in Actimab-A/venetoclax combination trial
|
| Dec 8 |
Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
|
| Dec 7 |
Actinium's Iomab-B shows encouraging action in late-stage leukemia study
|
| Dec 7 |
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting
|
| Dec 7 |
Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting
|
| Dec 7 |
Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting
|
| Dec 4 |
Actinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage Results
|
| Dec 3 |
Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting
|
| Dec 3 |
Is Actinium Pharmaceuticals (ATNM) A Good Stock To Buy Now?
|
| Dec 2 |
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know
|
| Dec 1 |
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
|
| Nov 29 |
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
|
| Nov 23 |
Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
|
| Nov 19 |
Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
|
